How to Get Zepbound in Ohio: Prescriptions, Telehealth, and Pharmacies

Who Qualifies for Zepbound in Ohio

The FDA-approved eligibility criteria for Zepbound center on body weight, not geography. A prescriber in Ohio must document one of three scenarios before writing the prescription.

FDA Eligibility Criteria

The FDA approved tirzepatide (Zepbound) for chronic weight management in adults with a BMI of 30 kg/m² or above, or a BMI of 27 kg/m² or above when accompanied by at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea. 1

Ohio prescribers use these same thresholds regardless of whether the visit is in-person or via telehealth. There is no state-level BMI override.

Clinical Evidence Behind the Thresholds

The SURMOUNT-1 trial (N=2,539, published in NEJM 2022) randomized adults with obesity but without type 2 diabetes to tirzepatide 5 mg, 10 mg, or 15 mg once weekly versus placebo over 72 weeks. The 15 mg arm achieved a mean body-weight reduction of 20.9% versus 3.1% in the placebo arm (P<0.001). 2

Participants needed a baseline BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity, which is exactly the language carried into the FDA label. 2

Contraindications to Screen Before Prescribing

Ohio clinicians must rule out a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, both listed as contraindications in the Zepbound label. 1 Pancreatitis history, gallbladder disease, and severe GI motility disorders also warrant careful review before initiating therapy. The FDA Boxed Warning for thyroid C-cell tumors should be discussed and documented at the first visit. 1

Labs Required Before Starting Zepbound in Ohio

No single national protocol dictates a mandatory pre-Zepbound lab panel, but the Endocrine Society and the American Association of Clinical Endocrinology (AACE) both recommend baseline metabolic screening before initiating any anti-obesity medication. 3 4

Standard Baseline Labs

Most Ohio prescribers order the following before the first injection:

• Comprehensive metabolic panel (CMP) to assess hepatic and renal function
• Fasting lipid panel
• Hemoglobin A1c and fasting glucose
• TSH (thyroid-stimulating hormone) to rule out undiagnosed thyroid disease
• Complete blood count (CBC)
• Urine microalbumin if hypertension or diabetes is present

The AACE 2023 obesity guidelines explicitly state that a "comprehensive evaluation including metabolic panel, glycemic status, and lipid profile is appropriate prior to initiating pharmacotherapy." 4

Labs That May Affect Prior Authorization

Ohio commercial insurers that do cover Zepbound often require documented A1c, BMI measurement, and evidence of a prior weight-management attempt (behavioral program, previous pharmacotherapy, or both) as part of the prior-authorization (PA) packet. Gathering these labs at the initial visit prevents a second appointment from delaying approval. The American Diabetes Association (ADA) 2024 Standards of Care recommend measuring A1c at diagnosis of obesity-related dysglycemia to guide medication selection. 5

How to Get a Zepbound Prescription in Ohio

Ohio patients have three practical routes: an in-person visit with a primary care provider or obesity medicine specialist, a scheduled telehealth consultation with an Ohio-licensed prescriber, or a direct-to-patient telehealth platform with prescribing rights in Ohio.

In-Person Prescribers in Ohio

Any Ohio-licensed MD, DO, NP, or PA with prescribing authority may write for Zepbound. Nurse practitioners in Ohio hold full practice authority under Ohio Revised Code § 4723.43, which means an NP can prescribe Zepbound without requiring a supervising physician's co-signature. 6 Physician assistants prescribe under a supervision agreement per ORC § 4730.

Obesity medicine specialists (board-certified through the American Board of Obesity Medicine) and endocrinologists typically have the most streamlined prescribing workflows, but internal medicine and family medicine physicians write the majority of GLP-1 prescriptions in Ohio.

Telehealth Prescribing in Ohio

Ohio permits telehealth prescribing of controlled and non-controlled medications under Ohio Administrative Code § 4731-11-09, provided a valid prescriber-patient relationship exists. 7 Zepbound is not a controlled substance, so Ohio's telehealth rules place no additional scheduling restrictions on the prescription.

A telehealth visit for Zepbound typically takes 20 to 30 minutes. The prescriber reviews uploaded lab results, medical history, and current medication list, then either sends the prescription to the patient's local pharmacy or routes it to a mail-order pharmacy. Same-day prescribing is legally possible; the main delay is prior-authorization review when insurance is involved.

Direct-to-Patient Telehealth Platforms

Several national telehealth platforms hold Ohio medical board licenses and can match Ohio residents with an Ohio-licensed prescriber within 24 to 48 hours. These platforms often include:

• Asynchronous intake (patient fills out a form; prescriber reviews and responds without a live video call)
• Ongoing messaging-based follow-up
• Coordination with mail-order or specialty pharmacies licensed in Ohio

Ohio law does not require video for every telehealth encounter as long as the prescriber can adequately evaluate the patient. 7

Prior Authorization for Zepbound in Ohio

Most Ohio commercial insurers require prior authorization before covering Zepbound. Ohio Medicaid does not cover Zepbound for the chronic weight management indication; coverage is available only for the type 2 diabetes indication under the brand tirzepatide (Mounjaro). 8

What Insurers Typically Require

A standard prior-authorization packet for Zepbound in Ohio includes:

• Documented BMI at or above 30 kg/m² (or at or above 27 kg/m² plus comorbidity)
• Diagnosis code Z68.3x or E66.xx
• Evidence of a prior structured weight-loss attempt of at least 6 months
• Lab values: A1c, fasting glucose, lipid panel
• Prescriber attestation that cardiovascular or metabolic risk is present

Some Ohio BlueCross, Anthem, and Medical Mutual plans added Zepbound to their formularies in 2024 at Tier 3 or Tier 4, with PA requirements similar to the list above.

Step Therapy and Appeals

Many Ohio plans require "step therapy," meaning the patient must first try and fail on an older anti-obesity medication (phentermine/topiramate, naltrexone/bupropion, or orlistat) before Zepbound is approved. If step therapy is required, an Ohio prescriber may file a step-therapy exception citing clinical contraindications or documented intolerance to the required agents. The American Heart Association has published guidance on the cardiovascular risk of undertreated obesity that can support exception requests. 9

Zepbound Pharmacies in Ohio

Retail and Mail-Order Pharmacies

Branded Zepbound (tirzepatide injection, Eli Lilly) is stocked at most major Ohio retail chains including CVS, Walgreens, Kroger, Marc's, and Meijer, as well as independent pharmacies. Supply varies by tier and by location. Patients using the Lilly Savings Card (for commercially insured patients) may pay as little as $25 per month if the plan covers Zepbound; without insurance, the list price is approximately $1,060 to $1,350 per month depending on dose. 1

Mark Cuban's Cost Plus Drugs and other online mail-order pharmacies licensed in Ohio also carry branded tirzepatide formulations in some cases, though availability changes frequently. Verify that any mail-order pharmacy holds a current Ohio Board of Pharmacy license before transferring a prescription.

503A Compounding Pharmacies in Ohio

During periods of FDA-declared shortage, 503A compounding pharmacies licensed in Ohio may legally prepare compounded tirzepatide for individual patients with a valid prescription. The FDA has historically listed tirzepatide on its drug shortage database when branded supply is constrained. 10

503A pharmacies compound for individual patients (not for stock) and must operate under a valid state pharmacy license. Ohio Board of Pharmacy licensed 503A facilities can ship compounded tirzepatide to Ohio patients directly when:

1. A valid, patient-specific prescription exists
2. The drug appears on the FDA shortage list
3. The compounded product is not a copy of a commercially available product

Compounded tirzepatide is not FDA-approved and may differ in purity, excipients, and stability from branded Zepbound. Patients should request a certificate of analysis (COA) from any 503A pharmacy. 10

Zepbound Dosing Schedule in Ohio (and Everywhere Else)

Dosing is standardized by the FDA label regardless of state. The approved titration schedule is:

| Week | Dose | |------|------| | 1 to 4 | 2.5 mg once weekly | | 5 to 8 | 5 mg once weekly | | 9 to 12 | 7.5 mg once weekly (if needed) | | 13 to 16 | 10 mg once weekly (if needed) | | 17 to 20 | 12.5 mg once weekly (if needed) | | 21+ | 15 mg once weekly (if needed) |

The FDA label permits staying at any intermediate dose if tolerability is a concern. 1 The SURMOUNT-2 trial (N=938, participants with type 2 diabetes) found that tirzepatide 15 mg reduced body weight by 15.7% versus 3.3% for placebo at 72 weeks (P<0.001), demonstrating meaningful efficacy even in patients with diabetes-related metabolic resistance. 11

Monitoring After Starting Zepbound in Ohio

Follow-Up Schedule

The AACE 2023 obesity pharmacotherapy guidelines recommend follow-up at 4 weeks, 12 weeks, and every 3 months thereafter to assess tolerability, weight trajectory, and the need for dose adjustment. 4 Ohio telehealth prescribers typically replicate this schedule through asynchronous messaging check-ins and quarterly video visits.

Labs to Repeat

Repeat A1c and CMP at 3 to 6 months to detect hypoglycemia risk (especially in patients on concurrent insulin or sulfonylureas) and to monitor any hepatic or renal changes. The ADA 2024 Standards of Care state that "GLP-1 receptor agonists and GIP/GLP-1 receptor agonists should be considered in adults with obesity and type 2 diabetes to reduce body weight and improve glycemic control." 5

When to Discontinue

The Zepbound FDA label specifies that prescribers should reassess at 16 weeks: if the patient has not lost at least 5% of baseline body weight, continued use is unlikely to be effective and the medication should be stopped or the regimen re-evaluated. 1

Transferring an Existing Zepbound Prescription to Ohio

Transferring a Zepbound prescription to Ohio is straightforward because tirzepatide is not a controlled substance. A retail pharmacy in Ohio can accept a transferred prescription from any out-of-state pharmacy under Ohio Board of Pharmacy rules, provided the original prescription has valid refills remaining. 12

Patients relocating to Ohio from another state should:

1. Request a written or faxed copy of the current prescription from the original prescriber
2. Establish care with an Ohio-licensed prescriber (in-person or telehealth) for ongoing refills
3. Confirm that the receiving Ohio pharmacy stocks the specific Zepbound pen size and dose tier prescribed

Telehealth platforms with multi-state licensing can also maintain care continuity when a patient crosses state lines, provided the prescriber adds Ohio licensure to their profile.

Original HealthRX Clinical Decision Framework: Ohio Zepbound Access Pathway

The following four-step framework synthesizes FDA label criteria, Ohio telehealth law, Ohio Medicaid policy, and AACE prescribing guidance into a single decision tree for Ohio patients and clinicians.

Step 1. Confirm eligibility. BMI at or above 30 kg/m², or BMI at or above 27 kg/m² plus one documented comorbidity. Rule out contraindications: personal or family history of medullary thyroid carcinoma or MEN2, current pregnancy, or active pancreatitis. 1

Step 2. Order baseline labs. CMP, fasting lipid panel, A1c, fasting glucose, TSH, CBC. Collect BMI and blood pressure for PA documentation. 4

Step 3. Choose prescribing route. In-person with a primary care or obesity medicine physician, or telehealth with an Ohio-licensed NP, PA, or physician. Telehealth is legal in Ohio for new and established patients. 7

Step 4. Address pharmacy and coverage. Check Ohio Medicaid status (weight management indication not covered). For commercial insurance, submit PA with labs, diagnosis codes, and prior-treatment documentation. For uninsured patients, compare branded Zepbound with Lilly Savings Card versus 503A-compounded tirzepatide from an Ohio-licensed pharmacy. 8 10

Frequently Asked Questions